Thermo Fisher Scientific Inc
TMO: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$569.00 | Cnq | Symxqlfbcj |
Thermo Fisher's Core Business Continues to Perform Well in Q3; Maintaining Our FVE
Against the backdrop of declining coronavirus revenue, wide-moat Thermo Fisher Scientific's third quarter was strong. The firm's core operations, buoyed by biopharma demand, grew 14% in the quarter, implying ongoing market share gains for the company. The outperformance led Thermo Fisher to slightly raise its annual guidance. We're maintaining our $590 fair value estimate and view shares as modestly undervalued.